Quantcast

Industry news that matters to you.  Learn more

Archives for September 2010

Thermo Fisher, Proteome Sciences Form Biomarker Alliance

Thermo Fisher Scientific today said that it will collaborate with Proteome Sciences to develop quantitative proteomic workflows for biomarker discovery and validation.

Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome

Agilent Technologies Inc. today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

DiagnoCure’s PCA3 Prostate Cancer Biomarker Submitted By Gen-Probe to the U.S. Food and Drug Administration

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that its commercial partner, Gen-Probe Incorporated, has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer. DiagnoCure holds the worldwide rights to the PCA3 biomarker and, in 2003, granted an exclusive sub-license to Gen-Probe for diagnostic applications.

New Clue to Diabetic Heart Disease Discovered

Scientists from King’s College London have identified a molecule that could help predict type 2 diabetes and identify diabetics that are most vulnerable to heart and circulatory disease.

Metabolic Test May Predict Pregnant Women at Risk for Preeclampsia

Women can be vulnerable to sudden, sometimes dangerous spikes in blood pressure during pregnancy, part of a condition called preeclampsia. And now scientists say they’ve developed a high-tech method to predict which women are most prone to preeclampsia in late pregnancy — long before symptoms arise.

The approach relies on so-called “metabolic profiling” to track telltale metabolites found in blood plasma. The researchers say these changes could be key indicators for preeclampsia risk.